HEADER OXIDOREDUCTASE, APOPTOSIS 02-JUL-13 4LII TITLE CRYSTAL STRUCTURE OF AN APOPTOSIS-INDUCING FACTOR, MITOCHONDRION- TITLE 2 ASSOCIATED, 1 (AIFM1) FROM HOMO SAPIENS AT 1.88 A RESOLUTION COMPND MOL_ID: 1; COMPND 2 MOLECULE: APOPTOSIS-INDUCING FACTOR 1, MITOCHONDRIAL; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: UNP RESIDUES 100-611; COMPND 5 SYNONYM: PROGRAMMED CELL DEATH PROTEIN 8; COMPND 6 EC: 1.-.-.-; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: AIF, AIFM1, BC111065, PDCD8; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: PB1; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: SPEEDET KEYWDS FLAVOPROTEIN, FAD/NAD-LINKED REDUCTASES, STRUCTURAL GENOMICS, JOINT KEYWDS 2 CENTER FOR STRUCTURAL GENOMICS, JCSG, PROTEIN STRUCTURE INITIATIVE, KEYWDS 3 PSI-BIOLOGY, OXIDOREDUCTASE, APOPTOSIS, PARTNERSHIP FOR T-CELL KEYWDS 4 BIOLOGY, TCELL EXPDTA X-RAY DIFFRACTION AUTHOR JOINT CENTER FOR STRUCTURAL GENOMICS (JCSG),PARTNERSHIP FOR T-CELL AUTHOR 2 BIOLOGY (TCELL) REVDAT 2 15-NOV-17 4LII 1 REMARK REVDAT 1 04-SEP-13 4LII 0 JRNL AUTH JOINT CENTER FOR STRUCTURAL GENOMICS (JCSG), JRNL AUTH 2 PARTNERSHIP FOR T-CELL BIOLOGY (TCELL) JRNL TITL CRYSTAL STRUCTURE OF AN APOPTOSIS-INDUCING FACTOR, JRNL TITL 2 MITOCHONDRION-ASSOCIATED, 1 (AIFM1) FROM HOMO SAPIENS AT JRNL TITL 3 1.88 A RESOLUTION JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 1.88 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.7.0032 REMARK 3 AUTHORS : MURSHUDOV,VAGIN,DODSON REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD WITH PHASES REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.88 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 44.90 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 97.4 REMARK 3 NUMBER OF REFLECTIONS : 42729 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.169 REMARK 3 R VALUE (WORKING SET) : 0.167 REMARK 3 FREE R VALUE : 0.211 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 2150 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.88 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.93 REMARK 3 REFLECTION IN BIN (WORKING SET) : 2948 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 97.29 REMARK 3 BIN R VALUE (WORKING SET) : 0.2910 REMARK 3 BIN FREE R VALUE SET COUNT : 170 REMARK 3 BIN FREE R VALUE : 0.3140 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3659 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 61 REMARK 3 SOLVENT ATOMS : 307 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 23.10 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 28.01 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 2.78000 REMARK 3 B22 (A**2) : -0.95000 REMARK 3 B33 (A**2) : -1.77000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -0.43000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.132 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.129 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.090 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 5.887 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.963 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.946 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 3855 ; 0.011 ; 0.019 REMARK 3 BOND LENGTHS OTHERS (A): 3748 ; 0.001 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 5228 ; 1.489 ; 1.991 REMARK 3 BOND ANGLES OTHERS (DEGREES): 8639 ; 0.764 ; 3.000 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 490 ; 5.783 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 165 ;31.884 ;23.576 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 647 ;14.094 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 31 ;21.098 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 576 ; 0.082 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 4333 ; 0.007 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): 861 ; 0.001 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1912 ; 2.452 ; 3.069 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): 1911 ; 2.446 ; 3.065 REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 2391 ; 3.480 ; 5.720 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 2 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A 125 A 545 REMARK 3 ORIGIN FOR THE GROUP (A): 18.4590 36.4170 1.9330 REMARK 3 T TENSOR REMARK 3 T11: 0.0080 T22: 0.0917 REMARK 3 T33: 0.1199 T12: 0.0053 REMARK 3 T13: -0.0007 T23: -0.0034 REMARK 3 L TENSOR REMARK 3 L11: 0.2165 L22: 0.2930 REMARK 3 L33: 0.7048 L12: 0.0870 REMARK 3 L13: -0.0937 L23: -0.0093 REMARK 3 S TENSOR REMARK 3 S11: -0.0153 S12: 0.0034 S13: 0.0144 REMARK 3 S21: 0.0205 S22: 0.0187 S23: 0.0025 REMARK 3 S31: 0.0315 S32: -0.0280 S33: -0.0034 REMARK 3 REMARK 3 TLS GROUP : 2 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A 559 A 611 REMARK 3 ORIGIN FOR THE GROUP (A): 7.4480 16.9400 -11.1880 REMARK 3 T TENSOR REMARK 3 T11: 0.1068 T22: 0.0763 REMARK 3 T33: 0.1180 T12: -0.0613 REMARK 3 T13: -0.0068 T23: -0.0042 REMARK 3 L TENSOR REMARK 3 L11: 1.3725 L22: 2.3055 REMARK 3 L33: 2.2935 L12: 0.5611 REMARK 3 L13: 0.3764 L23: -0.9266 REMARK 3 S TENSOR REMARK 3 S11: -0.0939 S12: 0.1215 S13: -0.0412 REMARK 3 S21: -0.1906 S22: 0.0801 S23: 0.0891 REMARK 3 S31: 0.3098 S32: -0.1054 S33: 0.0138 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL WITH MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: 1. HYDROGENS HAVE BEEN ADDED IN THE REMARK 3 RIDING POSITIONS. 2. ATOM RECORDS CONTAIN RESIDUAL B FACTORS REMARK 3 ONLY. 3. WATERS WERE EXCLUDED FROM AUTOMATIC TLS ASSIGNMENT. 4. REMARK 3 A MET-INHIBITION PROTOCOL WAS USED FOR SELENOMETHIONINE REMARK 3 INCORPORATION DURING PROTEIN EXPRESSION. THE OCCUPANCY OF THE SE REMARK 3 ATOMS IN THE MSE RESIDUES WAS REDUCED TO 0.75 FOR THE REDUCED REMARK 3 SCATTERING POWER DUE TO PARTIAL S-MET INCORPORATION. 5. 1,2- REMARK 3 ETHANEDIOL (EDO) FROM THE CRYOPROTECTION SOLUTION ARE MODELED. REMARK 3 6. FLAVIN-ADENINE DINUCLEOTIDE (FAD) IS MODELED BASED ON REMARK 3 ELECTRON DENSITY. REMARK 4 REMARK 4 4LII COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 08-JUL-13. REMARK 100 THE DEPOSITION ID IS D_1000080672. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 29-FEB-12 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRL REMARK 200 BEAMLINE : BL12-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9794 REMARK 200 MONOCHROMATOR : DOUBLE CRYSTAL SI(111) REMARK 200 OPTICS : RHODIUM-COATED VERTICAL AND REMARK 200 HORIZONTAL FOCUSING MIRRORS; REMARK 200 LIQUID-NITROGEN COOLED DOUBLE REMARK 200 CRYSTAL SI(111) MONOCHROMATOR REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XSCALE DECEMBER 29, 2011 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 42757 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.880 REMARK 200 RESOLUTION RANGE LOW (A) : 44.903 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 97.4 REMARK 200 DATA REDUNDANCY : 3.500 REMARK 200 R MERGE (I) : 0.11200 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 7.7300 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.88 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.95 REMARK 200 COMPLETENESS FOR SHELL (%) : 97.4 REMARK 200 DATA REDUNDANCY IN SHELL : 3.50 REMARK 200 R MERGE FOR SHELL (I) : 0.87200 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.600 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: SAD REMARK 200 SOFTWARE USED: SHELX, SHARP, SHELXD REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 49.58 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.44 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20.00% POLYETHYLENE GLYCOL 6000, 0.1M REMARK 280 MES PH 6.0, NANODROP, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE REMARK 280 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 44.90350 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: CRYSTAL PACKING ANALYSIS SUGGESTS THE ASSIGNMENT OF A REMARK 300 MONOMER AS THE SIGNIFICANT OLIGOMERIZATION STATE. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 0 REMARK 465 SER A 100 REMARK 465 GLY A 101 REMARK 465 LEU A 102 REMARK 465 GLY A 103 REMARK 465 LEU A 104 REMARK 465 THR A 105 REMARK 465 PRO A 106 REMARK 465 GLU A 107 REMARK 465 GLN A 108 REMARK 465 LYS A 109 REMARK 465 GLN A 110 REMARK 465 LYS A 111 REMARK 465 LYS A 112 REMARK 465 ALA A 113 REMARK 465 ALA A 114 REMARK 465 LEU A 115 REMARK 465 SER A 116 REMARK 465 ALA A 117 REMARK 465 SER A 118 REMARK 465 GLU A 119 REMARK 465 GLY A 120 REMARK 465 GLU A 121 REMARK 465 GLU A 122 REMARK 465 VAL A 123 REMARK 465 PRO A 124 REMARK 465 SER A 546 REMARK 465 THR A 547 REMARK 465 PRO A 548 REMARK 465 ALA A 549 REMARK 465 VAL A 550 REMARK 465 PRO A 551 REMARK 465 GLN A 552 REMARK 465 ALA A 553 REMARK 465 PRO A 554 REMARK 465 VAL A 555 REMARK 465 GLN A 556 REMARK 465 GLY A 557 REMARK 465 GLU A 558 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 126 107.88 -58.29 REMARK 500 LYS A 177 -104.05 -133.88 REMARK 500 ARG A 285 -33.26 -146.17 REMARK 500 GLU A 453 68.82 -119.49 REMARK 500 ALA A 473 66.35 38.04 REMARK 500 THR A 534 171.49 64.03 REMARK 500 LYS A 571 -4.98 68.38 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE FAD A 700 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EDO A 701 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EDO A 702 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: JCSG-422903 RELATED DB: TARGETTRACK REMARK 999 REMARK 999 SEQUENCE REMARK 999 THIS CONSTRUCT WAS EXPRESSED WITH AN N-TERMINAL PURIFICATION TAG REMARK 999 MGSDKIHHHHHHENLYFQG. THE TAG WAS REMOVED WITH TEV PROTEASE LEAVING REMARK 999 ONLY A GLYCINE (0) FOLLOWED BY RESIDUES 100-611 OF THE TARGET REMARK 999 SEQUENCE. NUMBERING IS BASED ON ISOFORM 1 OF UNIPROTKB ID O95831. DBREF 4LII A 100 611 UNP O95831 AIFM1_HUMAN 100 611 SEQADV 4LII GLY A 0 UNP O95831 EXPRESSION TAG SEQRES 1 A 513 GLY SER GLY LEU GLY LEU THR PRO GLU GLN LYS GLN LYS SEQRES 2 A 513 LYS ALA ALA LEU SER ALA SER GLU GLY GLU GLU VAL PRO SEQRES 3 A 513 GLN ASP LYS ALA PRO SER HIS VAL PRO PHE LEU LEU ILE SEQRES 4 A 513 GLY GLY GLY THR ALA ALA PHE ALA ALA ALA ARG SER ILE SEQRES 5 A 513 ARG ALA ARG ASP PRO GLY ALA ARG VAL LEU ILE VAL SER SEQRES 6 A 513 GLU ASP PRO GLU LEU PRO TYR MSE ARG PRO PRO LEU SER SEQRES 7 A 513 LYS GLU LEU TRP PHE SER ASP ASP PRO ASN VAL THR LYS SEQRES 8 A 513 THR LEU ARG PHE LYS GLN TRP ASN GLY LYS GLU ARG SER SEQRES 9 A 513 ILE TYR PHE GLN PRO PRO SER PHE TYR VAL SER ALA GLN SEQRES 10 A 513 ASP LEU PRO HIS ILE GLU ASN GLY GLY VAL ALA VAL LEU SEQRES 11 A 513 THR GLY LYS LYS VAL VAL GLN LEU ASP VAL ARG ASP ASN SEQRES 12 A 513 MSE VAL LYS LEU ASN ASP GLY SER GLN ILE THR TYR GLU SEQRES 13 A 513 LYS CYS LEU ILE ALA THR GLY GLY THR PRO ARG SER LEU SEQRES 14 A 513 SER ALA ILE ASP ARG ALA GLY ALA GLU VAL LYS SER ARG SEQRES 15 A 513 THR THR LEU PHE ARG LYS ILE GLY ASP PHE ARG SER LEU SEQRES 16 A 513 GLU LYS ILE SER ARG GLU VAL LYS SER ILE THR ILE ILE SEQRES 17 A 513 GLY GLY GLY PHE LEU GLY SER GLU LEU ALA CYS ALA LEU SEQRES 18 A 513 GLY ARG LYS ALA ARG ALA LEU GLY THR GLU VAL ILE GLN SEQRES 19 A 513 LEU PHE PRO GLU LYS GLY ASN MSE GLY LYS ILE LEU PRO SEQRES 20 A 513 GLU TYR LEU SER ASN TRP THR MSE GLU LYS VAL ARG ARG SEQRES 21 A 513 GLU GLY VAL LYS VAL MSE PRO ASN ALA ILE VAL GLN SER SEQRES 22 A 513 VAL GLY VAL SER SER GLY LYS LEU LEU ILE LYS LEU LYS SEQRES 23 A 513 ASP GLY ARG LYS VAL GLU THR ASP HIS ILE VAL ALA ALA SEQRES 24 A 513 VAL GLY LEU GLU PRO ASN VAL GLU LEU ALA LYS THR GLY SEQRES 25 A 513 GLY LEU GLU ILE ASP SER ASP PHE GLY GLY PHE ARG VAL SEQRES 26 A 513 ASN ALA GLU LEU GLN ALA ARG SER ASN ILE TRP VAL ALA SEQRES 27 A 513 GLY ASP ALA ALA CYS PHE TYR ASP ILE LYS LEU GLY ARG SEQRES 28 A 513 ARG ARG VAL GLU HIS HIS ASP HIS ALA VAL VAL SER GLY SEQRES 29 A 513 ARG LEU ALA GLY GLU ASN MSE THR GLY ALA ALA LYS PRO SEQRES 30 A 513 TYR TRP HIS GLN SER MSE PHE TRP SER ASP LEU GLY PRO SEQRES 31 A 513 ASP VAL GLY TYR GLU ALA ILE GLY LEU VAL ASP SER SER SEQRES 32 A 513 LEU PRO THR VAL GLY VAL PHE ALA LYS ALA THR ALA GLN SEQRES 33 A 513 ASP ASN PRO LYS SER ALA THR GLU GLN SER GLY THR GLY SEQRES 34 A 513 ILE ARG SER GLU SER GLU THR GLU SER GLU ALA SER GLU SEQRES 35 A 513 ILE THR ILE PRO PRO SER THR PRO ALA VAL PRO GLN ALA SEQRES 36 A 513 PRO VAL GLN GLY GLU ASP TYR GLY LYS GLY VAL ILE PHE SEQRES 37 A 513 TYR LEU ARG ASP LYS VAL VAL VAL GLY ILE VAL LEU TRP SEQRES 38 A 513 ASN ILE PHE ASN ARG MSE PRO ILE ALA ARG LYS ILE ILE SEQRES 39 A 513 LYS ASP GLY GLU GLN HIS GLU ASP LEU ASN GLU VAL ALA SEQRES 40 A 513 LYS LEU PHE ASN ILE HIS MODRES 4LII MSE A 171 MET SELENOMETHIONINE MODRES 4LII MSE A 242 MET SELENOMETHIONINE MODRES 4LII MSE A 340 MET SELENOMETHIONINE MODRES 4LII MSE A 353 MET SELENOMETHIONINE MODRES 4LII MSE A 364 MET SELENOMETHIONINE MODRES 4LII MSE A 469 MET SELENOMETHIONINE MODRES 4LII MSE A 481 MET SELENOMETHIONINE MODRES 4LII MSE A 585 MET SELENOMETHIONINE HET MSE A 171 8 HET MSE A 242 13 HET MSE A 340 8 HET MSE A 353 8 HET MSE A 364 8 HET MSE A 469 8 HET MSE A 481 8 HET MSE A 585 8 HET FAD A 700 53 HET EDO A 701 4 HET EDO A 702 4 HETNAM MSE SELENOMETHIONINE HETNAM FAD FLAVIN-ADENINE DINUCLEOTIDE HETNAM EDO 1,2-ETHANEDIOL HETSYN EDO ETHYLENE GLYCOL FORMUL 1 MSE 8(C5 H11 N O2 SE) FORMUL 2 FAD C27 H33 N9 O15 P2 FORMUL 3 EDO 2(C2 H6 O2) FORMUL 5 HOH *307(H2 O) HELIX 1 1 GLY A 140 ASP A 154 1 15 HELIX 2 2 ARG A 172 PHE A 181 5 10 HELIX 3 3 ASN A 186 LEU A 191 1 6 HELIX 4 4 PRO A 207 TYR A 211 5 5 HELIX 5 5 LEU A 267 ARG A 272 1 6 HELIX 6 6 GLY A 274 ARG A 280 1 7 HELIX 7 7 LYS A 286 VAL A 300 1 15 HELIX 8 8 GLY A 309 GLY A 327 1 19 HELIX 9 9 PRO A 345 GLU A 359 1 15 HELIX 10 10 LEU A 406 GLY A 411 1 6 HELIX 11 11 HIS A 454 MSE A 469 1 16 HELIX 12 12 ASN A 516 GLY A 525 1 10 HELIX 13 13 ILE A 528 GLU A 533 1 6 HELIX 14 14 ARG A 584 GLY A 595 1 12 HELIX 15 15 ASP A 600 ALA A 605 1 6 HELIX 16 16 LYS A 606 ASN A 609 5 4 SHEET 1 A 6 GLY A 224 THR A 229 0 SHEET 2 A 6 ARG A 158 SER A 163 1 N ILE A 161 O LEU A 228 SHEET 3 A 6 HIS A 131 ILE A 137 1 N LEU A 136 O LEU A 160 SHEET 4 A 6 GLN A 250 ILE A 258 1 O LEU A 257 N ILE A 137 SHEET 5 A 6 MSE A 242 LEU A 245 -1 N VAL A 243 O ILE A 251 SHEET 6 A 6 VAL A 233 ASP A 237 -1 N ASP A 237 O MSE A 242 SHEET 1 B 6 GLY A 224 THR A 229 0 SHEET 2 B 6 ARG A 158 SER A 163 1 N ILE A 161 O LEU A 228 SHEET 3 B 6 HIS A 131 ILE A 137 1 N LEU A 136 O LEU A 160 SHEET 4 B 6 GLN A 250 ILE A 258 1 O LEU A 257 N ILE A 137 SHEET 5 B 6 ILE A 433 VAL A 435 1 O TRP A 434 N ILE A 258 SHEET 6 B 6 GLN A 428 ARG A 430 -1 N ALA A 429 O ILE A 433 SHEET 1 C 2 ARG A 192 LYS A 194 0 SHEET 2 C 2 GLU A 200 SER A 202 -1 O ARG A 201 N PHE A 193 SHEET 1 D 2 GLY A 262 PRO A 264 0 SHEET 2 D 2 LEU A 400 PRO A 402 -1 O GLU A 401 N THR A 263 SHEET 1 E 5 THR A 281 LEU A 283 0 SHEET 2 E 5 HIS A 393 ALA A 396 1 O ALA A 396 N THR A 282 SHEET 3 E 5 SER A 302 ILE A 306 1 N ILE A 306 O VAL A 395 SHEET 4 E 5 GLU A 329 LEU A 333 1 O ILE A 331 N ILE A 305 SHEET 5 E 5 LYS A 362 MSE A 364 1 O MSE A 364 N GLN A 332 SHEET 1 F 3 VAL A 369 SER A 375 0 SHEET 2 F 3 LYS A 378 LEU A 383 -1 O LYS A 378 N SER A 375 SHEET 3 F 3 LYS A 388 THR A 391 -1 O VAL A 389 N ILE A 381 SHEET 1 G 3 PHE A 421 ARG A 422 0 SHEET 2 G 3 ALA A 440 ASP A 444 1 O CYS A 441 N PHE A 421 SHEET 3 G 3 GLY A 448 ARG A 450 -1 O GLY A 448 N ASP A 444 SHEET 1 H 5 MSE A 481 ASP A 485 0 SHEET 2 H 5 GLY A 491 GLY A 496 -1 O TYR A 492 N SER A 484 SHEET 3 H 5 VAL A 572 TRP A 579 -1 O LEU A 578 N GLU A 493 SHEET 4 H 5 LYS A 562 ARG A 569 -1 N GLY A 563 O TRP A 579 SHEET 5 H 5 THR A 504 ALA A 509 -1 N VAL A 505 O PHE A 566 LINK C TYR A 170 N MSE A 171 1555 1555 1.33 LINK C MSE A 171 N ARG A 172 1555 1555 1.34 LINK C ASN A 241 N MSE A 242 1555 1555 1.33 LINK C MSE A 242 N VAL A 243 1555 1555 1.33 LINK C ASN A 339 N MSE A 340 1555 1555 1.33 LINK C MSE A 340 N GLY A 341 1555 1555 1.34 LINK C THR A 352 N MSE A 353 1555 1555 1.33 LINK C MSE A 353 N GLU A 354 1555 1555 1.33 LINK C VAL A 363 N MSE A 364 1555 1555 1.33 LINK C MSE A 364 N PRO A 365 1555 1555 1.35 LINK C ASN A 468 N MSE A 469 1555 1555 1.33 LINK C MSE A 469 N THR A 470 1555 1555 1.33 LINK C SER A 480 N MSE A 481 1555 1555 1.33 LINK C MSE A 481 N PHE A 482 1555 1555 1.33 LINK C ARG A 584 N MSE A 585 1555 1555 1.33 LINK C MSE A 585 N PRO A 586 1555 1555 1.35 SITE 1 AC1 35 GLY A 138 GLY A 139 GLY A 140 THR A 141 SITE 2 AC1 35 ALA A 142 VAL A 162 GLU A 164 ASP A 165 SITE 3 AC1 35 ARG A 172 PRO A 173 SER A 176 LYS A 177 SITE 4 AC1 35 LYS A 232 VAL A 233 ALA A 259 THR A 260 SITE 5 AC1 35 GLY A 261 ARG A 285 LYS A 286 GLY A 437 SITE 6 AC1 35 ASP A 438 GLU A 453 HIS A 454 HIS A 455 SITE 7 AC1 35 ALA A 458 PHE A 482 TRP A 483 HOH A 803 SITE 8 AC1 35 HOH A 804 HOH A 805 HOH A 818 HOH A 837 SITE 9 AC1 35 HOH A 840 HOH A1002 HOH A1065 SITE 1 AC2 5 LEU A 168 TYR A 211 VAL A 212 ALA A 226 SITE 2 AC2 5 VAL A 227 SITE 1 AC3 6 GLY A 309 MSE A 340 GLY A 341 LYS A 342 SITE 2 AC3 6 HOH A 807 HOH A 867 CRYST1 50.680 89.807 60.471 90.00 94.78 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019732 0.000000 0.001650 0.00000 SCALE2 0.000000 0.011135 0.000000 0.00000 SCALE3 0.000000 0.000000 0.016595 0.00000